Innate Pharma plans IND of ADC candidate after positive preclinical data

Innate Pharma plans to advance IPH45 towards clinical trials, with an investigational new drug (IND) application planned in 2024.

Related Posts

OncoVerity eyes cusatuzumab development in AML after li...

Mar 29, 2023

Sotigalimab by Pyxis Oncology for Glioma: Likelihood of...

Oct 27, 2023

Illumina to divest Grail after two years of lawsuits 

Dec 18, 2023